1
|
Castelo-Branco C, Cancelo Hidalgo MJ, Palacios S, Ciria-Recasens M, Fernández-Pareja A, Carbonell-Abella C, Manasanch J, Haya-Palazuelos J. Efficacy and safety of ossein-hydroxyapatite complex versus calcium carbonate to prevent bone loss. Climacteric 2019; 23:252-258. [PMID: 31747785 DOI: 10.1080/13697137.2019.1685488] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
Abstract
Objective: This study aimed to compare the efficacy and safety of ossein-hydroxyapatite complex (OHC) versus calcium carbonate (CC) for preventing bone loss during perimenopause in current clinical practice.Methods: The prospective, comparative, non-randomized, open-label study included 851 perimenopausal women with basal bone mineral density (BMD) T-score ≥-2 standard deviations (SDs). Participants received either OHC (712 mg calcium/day) or CC (1000 mg calcium/day) over 3 years. BMD was evaluated by dual-energy X-ray absorptiometry at the lumbar spine (L2-L4) at baseline and after 18 and 36 months of follow-up. Adverse drug reactions (ADRs) were also recorded.Results: In women receiving OHC, BMD at the L2-L4 site remained stable over the 3-year follow-up period (mean [SD] change 0.00 [0.11] g/cm2). BMD in the CC arm decreased -3.1% (mean [SD] - 0.03 [0.11] g/cm2). Between-group differences were statistically significant (p < 0.001) and favored OHC. ADRs were more frequent in the CC group (7.7% vs. 2.7% in the OHC group; p = 0.001), affecting primarily the gastrointestinal system.Conclusion: OHC showed greater efficacy and tolerability than CC for bone loss prevention in perimenopausal women in real-world practice. As the daily dose of calcium was higher in the CC group, the differences might be linked to the ossein compound in OHC.
Collapse
Affiliation(s)
- C Castelo-Branco
- Clinic Institute of Gynecology, Obstetrics and Neonatology, Hospital Clinic-Institut d'Investigacions Biomédiques August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain
| | - M J Cancelo Hidalgo
- Obstetrics and Gynaecology Department, Hospital Universitario de Guadalajara, Guadalajara, Spain.,Universidad de Alcalá, Alcalá de Henares (Madrid), Spain
| | - S Palacios
- Director of Palacios Institute of Woman's Health, Madrid, Spain
| | - M Ciria-Recasens
- Rheumatology Department, Parc de Salud Mar, Hospital Universitari del Mar, Barcelona, Spain
| | - A Fernández-Pareja
- CMSc, Departamento I de Prevención y Promoción de la Salud Hortaleza, Madrid, Spain
| | - C Carbonell-Abella
- Primary Care Health Centre Vía Roma, Universitat de Barcelona, Barcelona, Spain
| | - J Manasanch
- Pierre Fabre Ibérica, Dep. Médico-Científico, Barcelona, Spain
| | - J Haya-Palazuelos
- Obstetrics and Gynaecology Department, Hospital General Universitario de Ciudad Real, Ciudad Real, Spain
| |
Collapse
|
2
|
Musson DS, Gao R, Watson M, Lin JM, Park YE, Tuari D, Callon KE, Zhu M, Dalbeth N, Naot D, Munro JT, Cornish J. Bovine bone particulates containing bone anabolic factors as a potential xenogenic bone graft substitute. J Orthop Surg Res 2019; 14:60. [PMID: 30786911 PMCID: PMC6383243 DOI: 10.1186/s13018-019-1089-x] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/20/2018] [Accepted: 02/05/2019] [Indexed: 02/08/2023] Open
Abstract
Background Alternative grafts are needed to improve the healing of bone non-union. Here, we assessed a bovine bone product which retains the inorganic and organic components of bone, as an alternative bone graft. Methods Bovine bone matrix proteins (BBMPs) were isolated from bovine bone particulates (BBPs) and tested in vitro. Primary rat osteoblast viability, differentiation, and mineralisation were assessed with alamarBlue®, real-time PCR, and von Kossa staining assays, respectively. Osteoclast formation was assessed in primary murine bone marrow cultures with TRAP staining. Human osteoblast growth and differentiation in the presence of BBPs was evaluated in 3D collagen gels in vitro using alamarBlue® and real-time PCR, respectively. The efficacy of BBPs as an alternative bone graft was tested in a rat critical-size calvarial defect model, with histology scored at 4 and 12 weeks post-surgery. Results In vitro, the highest concentration of BBMPs increased mineral deposition five-fold compared to the untreated control group (P < 0.05); enhanced the expression of key osteoblast genes encoding for RUNX2, alkaline phosphatase, and osteocalcin (P < 0.05); and decreased osteoclast formation three-fold, compared to the untreated control group (P < 0.05). However, the BBPs had no effect on primary human osteoblasts in vitro, and in vivo, no difference was found in healing between the BBP-treated group and the untreated control group. Conclusions Overall, despite the positive effects of the BBMPs on the cells of the bone, the bovine bone product as a whole did not enhance bone healing. Finding a way to harness the positive effect of these BBMPs would provide a clear benefit for healing bone non-union.
Collapse
Affiliation(s)
- David S Musson
- Department of Medicine, University of Auckland, Auckland, 1142, New Zealand.
| | - Ryan Gao
- Department of Medicine, University of Auckland, Auckland, 1142, New Zealand
| | - Maureen Watson
- Department of Medicine, University of Auckland, Auckland, 1142, New Zealand
| | - Jian-Ming Lin
- Department of Medicine, University of Auckland, Auckland, 1142, New Zealand
| | - Young-Eun Park
- Department of Medicine, University of Auckland, Auckland, 1142, New Zealand
| | - Donna Tuari
- Department of Medicine, University of Auckland, Auckland, 1142, New Zealand
| | - Karen E Callon
- Department of Medicine, University of Auckland, Auckland, 1142, New Zealand
| | - Mark Zhu
- Department of Medicine, University of Auckland, Auckland, 1142, New Zealand.,Auckland City Hospital, Auckland District Health Board, Auckland, 1023, New Zealand
| | - Nicola Dalbeth
- Department of Medicine, University of Auckland, Auckland, 1142, New Zealand
| | - Dorit Naot
- Department of Medicine, University of Auckland, Auckland, 1142, New Zealand
| | - Jacob T Munro
- Auckland City Hospital, Auckland District Health Board, Auckland, 1023, New Zealand.,Department of Surgery, University of Auckland, Auckland, 1142, New Zealand
| | - Jillian Cornish
- Department of Medicine, University of Auckland, Auckland, 1142, New Zealand
| |
Collapse
|
3
|
Rüegsegger P, Keller A, Dambacher MA. Comparison of the treatment effects of ossein-hydroxyapatite compound and calcium carbonate in osteoporotic females. Osteoporos Int 1995; 5:30-4. [PMID: 7703621 DOI: 10.1007/bf01623655] [Citation(s) in RCA: 25] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Abstract
The aim of the study was to evaluate whether ossein-hydroxyapatite (OHC) is more effective than calcium carbonate (CC) in preventing further bone loss in postmenopausal osteoporosis. Forty osteoporotic patients were monitored for 20 months. The patients were randomly assigned to one of two groups and treated in a double-masked manner with 1400 mg calcium per day, in the form of either OHC or CC. OHC consists of hydroxyapatite, collagens and non-collagenous proteins/peptides containing insulin-like growth factor I (IGF-I; 1341 ng), insulin-like growth factor II (IGF-II; 670 ng), transforming growth factor beta (TGF-beta; 166 ng) and osteocalcin (47 micrograms). The bone densities were evaluated at intervals of 4 months with high-precision peripheral quantitative computed tomography. After 20 months of treatment the loss of trabecular bone was 0.8 +/- 0.5% in the OHC group and 1.8 +/- 0.7% in the CC group. The difference between the OHC and CC groups was statistically significant. This study shows that OHC is more effective than CC in slowing peripheral trabecular bone loss in patients with manifest osteoporosis.
Collapse
Affiliation(s)
- P Rüegsegger
- Institute for Biomedical Engineering, University and Federal Institute of Technology, Zurich, Switzerland
| | | | | |
Collapse
|